L Peyrin-Biroulet

Summary

Publications

  1. doi request reprint French national consensus clinical guidelines for the management of Crohn's disease
    Laurent Peyrin-Biroulet
    University Hospital of Nancy, Department of Gastroenterology, Vandoeuvre, France Electronic address
    Dig Liver Dis . 2016
  2. doi request reprint Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis
    Laurent Peyrin-Biroulet
    Department of Gastroenterology, Université de Lorraine, Vandœuvre lès Nancy, France Electronic address
    Clin Gastroenterol Hepatol . 2016
  3. doi request reprint Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations
    Laurent Peyrin-Biroulet
    Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Allee du Morvan, 54 511 Vandœuvre lès Nancy, France
    J Crohns Colitis 11:128-133. 2017
  4. doi request reprint Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease
    Laurent Peyrin-Biroulet
    Gastroenterology Department, Lorraine University, Vandoeuvre, France Electronic address
    Clin Gastroenterol Hepatol 15:25-36.e27. 2017
  5. doi request reprint French national consensus clinical guidelines for the management of ulcerative colitis
    Laurent Peyrin-Biroulet
    Service d Hepato Gastroenterologie, CHU de Nancy, Vandœuvre lès Nancy, France Electronic address
    Dig Liver Dis 48:726-33. 2016
  6. doi request reprint Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study
    Laurent Peyrin-Biroulet
    Department of Hepato Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre les Nancy, France Electronic address
    Dig Liver Dis 48:601-7. 2016
  7. pmc Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience
    Laurent Peyrin-Biroulet
    Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Nancy, France
    J Crohns Colitis 10:516-24. 2016
  8. doi request reprint Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
    Laurent Peyrin-Biroulet
    INSERM Unité 954 and Department of Gastroenterology, University of Lorraine, Nancy, France Electronic address
    Clin Gastroenterol Hepatol 14:348-354.e17. 2016
  9. doi request reprint Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review
    Laurent Peyrin-Biroulet
    National Institute of Health and Medical Research, U954, and Hepato Gastroenterology Department of Lorraine University, Vandoeuvre les Nancy, France
    Am J Clin Nutr 102:1585-94. 2015
  10. doi request reprint Histologic remission: the ultimate therapeutic goal in ulcerative colitis?
    Laurent Peyrin-Biroulet
    INSERM, U954, France Department of Hepato Gastroenterology, University Hospital of Nancy, Universite Henri Poincare, Vandoeuvre les Nancy, France Electronic address
    Clin Gastroenterol Hepatol 12:929-34.e2. 2014

Detail Information

Publications42

  1. doi request reprint French national consensus clinical guidelines for the management of Crohn's disease
    Laurent Peyrin-Biroulet
    University Hospital of Nancy, Department of Gastroenterology, Vandoeuvre, France Electronic address
    Dig Liver Dis . 2016
    ..There is limited evidence supporting CD management in specific clinical situations, thus precluding an evidence-based approach...
  2. doi request reprint Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis
    Laurent Peyrin-Biroulet
    Department of Gastroenterology, Université de Lorraine, Vandœuvre lès Nancy, France Electronic address
    Clin Gastroenterol Hepatol . 2016
    ..The aim of this article was to review the current evidence to assess the feasibility, value, and impact of integrating continuous clinical response (CCR) as a patient-reported outcome into routine management of UC...
  3. doi request reprint Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations
    Laurent Peyrin-Biroulet
    Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Allee du Morvan, 54 511 Vandœuvre lès Nancy, France
    J Crohns Colitis 11:128-133. 2017
    ..The aim of this survey was to find out the patients' perspectives concerning biosimilars...
  4. doi request reprint Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease
    Laurent Peyrin-Biroulet
    Gastroenterology Department, Lorraine University, Vandoeuvre, France Electronic address
    Clin Gastroenterol Hepatol 15:25-36.e27. 2017
    ..This systematic review investigated the efficacy and the effectiveness of biologic drugs in extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD)...
  5. doi request reprint French national consensus clinical guidelines for the management of ulcerative colitis
    Laurent Peyrin-Biroulet
    Service d Hepato Gastroenterologie, CHU de Nancy, Vandœuvre lès Nancy, France Electronic address
    Dig Liver Dis 48:726-33. 2016
    ..The disease progresses over time, and clinical management guidelines should reflect its dynamic nature. There is limited evidence supporting UC management in specific clinical situations, thus precluding an evidence-based approach...
  6. doi request reprint Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study
    Laurent Peyrin-Biroulet
    Department of Hepato Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre les Nancy, France Electronic address
    Dig Liver Dis 48:601-7. 2016
    ..Ulcerative colitis (UC) is a life time disease and issues with therapy may impact on patient satisfaction and treatment preferences...
  7. pmc Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience
    Laurent Peyrin-Biroulet
    Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Nancy, France
    J Crohns Colitis 10:516-24. 2016
    ..Anti-tumour necrosis factor [TNF] therapy in combination with thiopurine is the most effective strategy for Crohn's disease, but raises safety concerns...
  8. doi request reprint Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
    Laurent Peyrin-Biroulet
    INSERM Unité 954 and Department of Gastroenterology, University of Lorraine, Nancy, France Electronic address
    Clin Gastroenterol Hepatol 14:348-354.e17. 2016
    ..This is increasingly important to guide current therapeutic strategies for IBD and to develop treatment algorithms for clinical practice. ..
  9. doi request reprint Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review
    Laurent Peyrin-Biroulet
    National Institute of Health and Medical Research, U954, and Hepato Gastroenterology Department of Lorraine University, Vandoeuvre les Nancy, France
    Am J Clin Nutr 102:1585-94. 2015
    ..Guidelines on the diagnosis and treatment of iron deficiency (ID) vary widely across indications...
  10. doi request reprint Histologic remission: the ultimate therapeutic goal in ulcerative colitis?
    Laurent Peyrin-Biroulet
    INSERM, U954, France Department of Hepato Gastroenterology, University Hospital of Nancy, Universite Henri Poincare, Vandoeuvre les Nancy, France Electronic address
    Clin Gastroenterol Hepatol 12:929-34.e2. 2014
    ..We also highlight questions that will require careful consideration if histologic remission is to become more widely used as an end point in clinical trials and a treatment goal in clinical practice. ..
  11. ncbi request reprint Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment
    Lucine Vuitton
    INSERM U954 and Department of Hepato Gastroenterology, University Hospital of Nancy Brabois, Université Henri Poincaré 1 Allée du Morvan, 54511 Vandoeuvre les Nancy, France
    Curr Drug Targets 14:1385-91. 2013
    ..First data in IBD are promising, especially in ulcerative colitis. Ongoing clinical trials in both UC and Crohn's disease (CD) are needed to further explore its efficacy in CD and to better assess its safety profile. ..
  12. doi request reprint Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process
    Laurent Peyrin-Biroulet
    INSERM U954 and Department of Hepato Gastroenterology, University Hospital of Nancy, Université Henri Poincaré 1, Vandoeuvre les Nancy, France
    Am J Gastroenterol 107:1770-6. 2012
    ..The participants then derived a final definition, based on best current knowledge, that it is hoped will be of practical use in disease-modification trials in CD...
  13. doi request reprint Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008)
    Laurent Peyrin-Biroulet
    INSERM, U954 and Department of Hepato Gastroenterology, University Hospital of Nancy, Université Henri Poincaré 1, Vandoeuvre les Nancy, France
    Inflamm Bowel Dis 18:2247-51. 2012
    ..Few data are available on the incidence, characteristics, treatment, and prognosis of inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) in population-based cohorts...
  14. ncbi request reprint Capsule endoscopy in Crohn's disease
    Jean Baptiste Chevaux
    INSERM U954 and Department of Hepato Gastroenterology, Nancy University Hospital, Allee du Morvan, Vandoeuvre les Nancy, France
    Curr Drug Targets 13:1261-7. 2012
    ..Furthermore, there are no validated CD diagnosis criteria for CE and no severity indexes have been independently validated. The role of CE in evaluating mucosal healing and postoperative recurrence will require additional investigation...
  15. doi request reprint Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience
    Laurent Peyrin-Biroulet
    INSERM, U954 and Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Inflamm Bowel Dis 18:697-702. 2012
    ..Cystitis is the most common genitourinary complication in Crohn's disease (CD). We assessed the prevalence of and risk factors for urinary tract infections (UTI) in inflammatory bowel diseases (IBD)...
  16. doi request reprint Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease
    Laurent Peyrin-Biroulet
    Department of Hepato Gastroenterology, University Hospital of Nancy Brabois, Vandoeuvre les Nancy, France
    Gut 60:930-6. 2011
    ..The aim of the study was to assess whether azathioprine and antitumour necrosis factor (TNF) treatment decrease the long-term need for surgery in patients with Crohn's disease...
  17. doi request reprint The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts
    L Peyrin-Biroulet
    Inserm U954, Henri Poincaré University Nancy 1, University Hospital of Nancy, Allée du Morvan 54, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 33:707-13. 2011
    ..Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients...
  18. doi request reprint Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
    Laurent Peyrin-Biroulet
    INSERM Unité 954 and Department of Gastroenterology, University Hospital of Nancy, Henri Poincare University, Vandœuvre lès Nancy, France
    Gastroenterology 141:1621-28.e1-5. 2011
    ..Patients with inflammatory bowel disease (IBD) who have been exposed to thiopurines might have an increased risk of skin cancer. We assessed this risk among patients in France...
  19. doi request reprint Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience
    A Oussalah
    INSERM, U724, and Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 28:966-72. 2008
    ..Adalimumab may be effective in inducing remission in patients with mild-to-moderate ulcerative colitis who had secondary failure to infliximab...
  20. doi request reprint Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey
    A Oussalah
    INSERM, U954 and Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 30:854-63. 2009
    ..Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain...
  21. doi request reprint Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience
    D Laharie
    Service d Hepato Gastroenterologie, Hopital Haut Leveque, CHU de Bordeaux, Pessac, France
    Aliment Pharmacol Ther 37:998-1004. 2013
    ..Mucosal healing can be achieved with infliximab (IFX)...
  22. doi request reprint TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine
    L Peyrin-Biroulet
    INSERM U724, Service d Hepatogastroenterologie, CHU de Nancy, France
    Gastroenterol Clin Biol 33:23-30. 2009
    ..We conducted a survey of nonacademic gastroenterologists to evaluate the use of tumor necrosis factor (TNF) antagonists in inflammatory bowel disease (IBD)...
  23. doi request reprint Inflammatory bowel disease and hepatitis B and C
    J B Chevaux
    INSERM U724, CHU de Nancy, Vandoeuvre, France
    Gastroenterol Clin Biol 33:1082-93. 2009
    ..Physicians managing IBD patients should be aware of the need for screening and institute preventive measures against B and C hepatitis...
  24. doi request reprint [Helminths and inflammatory bowel diseases]
    C Laclotte
    INSERM, U724, France
    Gastroenterol Clin Biol 32:1064-74. 2008
    ..Exposure to helminths may be effective in treating inflammatory bowel diseases and was well tolerated, according to the results of few studies. Its long-term safety remains unknown...
  25. ncbi request reprint Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study
    L Peyrin-Biroulet
    Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 25:675-80. 2007
    ..Adalimumab is effective in inducing remission in patients with active Crohn's disease who had secondary failure to infliximab therapy...
  26. doi request reprint Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience
    A Oussalah
    INSERM, U724, and Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 29:416-23. 2009
    ..Adalimumab is effective in inducing clinical remission in patients with Crohn's disease who lost response or became intolerant to infliximab...
  27. ncbi request reprint Anti-TNF therapy in inflammatory bowel diseases: a huge review
    L Peyrin-Biroulet
    INSERM, U954 and Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Minerva Gastroenterol Dietol 56:233-43. 2010
    ..an indiscriminate use of anti-TNF agents modify the natural course of the disease, should mucosal healing be used in clinical practice, and should anti-TNF therapy be used alone or in combination with immunomodulators in the long-term?..
  28. doi request reprint Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn's disease
    A Oussalah
    INSERM U954 and Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 32:1135-44. 2010
    ..Serum procalcitonin level may reflect non-infectious inflammation...
  29. doi request reprint Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease
    A Buisson
    Department of Hepato Gastroenterology, University Hospital Estaing of Clermont Ferrand, Universite d Auvergne, France
    Aliment Pharmacol Ther 35:1175-80. 2012
    ..While methotrexate is the most frequently used systemic treatment for psoriasis, its efficacy for psoriasiform lesions related to anti-TNF therapy remains unknown...
  30. doi request reprint Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression
    L Peyrin-Biroulet
    INSERM, U724, and Department of Hepato Gastroenterology, University Hospital of Nancy, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 28:984-93. 2008
    ..The interaction of ribavirin, an inosine monophosphate dehydrogenase inhibitor, with azathioprine metabolism, potentially leading to myelotoxicity, remains unexplored...
  31. doi request reprint Infliximab for refractory ulcerative proctitis
    G Bouguen
    INSERM, Department of Hepato Gastroenterology, University Hospital of Rennes, Pontchaillou, France
    Aliment Pharmacol Ther 31:1178-85. 2010
    ..Efficacy of infliximab in treating ulcerative proctitis remains unknown...
  32. pmc Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
    L Marthey
    Department of Gastroenterology, Kremlin Bicetre Hospital, Assistance Publique Hopitaux de Paris AP HP, Paris Sud University, Le Kremlin Bicetre, France Department of Gastroenterology, Antoine Beclere Hospital, Assistance Publique Hopitaux de Paris AP HP, Paris Sud University, Clamart, France
    J Crohns Colitis 10:395-401. 2016
    ..Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity...
  33. doi request reprint Review article: the natural history of postoperative Crohn's disease recurrence
    A Buisson
    Department of Hepato Gastroenterology, University Hospital Estaing of Clermont Ferrand, Auvergne University, Clermont Ferrand, France
    Aliment Pharmacol Ther 35:625-33. 2012
    ..Surgical resection of the diseased bowel in Crohn's disease is unfortunately not curative, and postoperative recurrence remains a problem in these patients...
  34. doi request reprint Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases
    A Oussalah
    Inserm U954, Cellular and Molecular Pathology in Nutrition, Henri Poincaré University Nancy 1, and University Hospital of Nancy, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 34:1173-84. 2011
    ..The magnitude of association between homocysteine metabolism and inflammatory bowel diseases (IBD) remains unknown, whereas the association between hyperhomocysteinaemia and thrombosis remains controversial in IBD...
  35. doi request reprint Review article: remission rates achievable by current therapies for inflammatory bowel disease
    L Peyrin-Biroulet
    INSERM U954 and Department of Hepato Gastroenterology, University Hospital of Nancy, Henri Poincare University, Vandœuvre lès Nancy, France
    Aliment Pharmacol Ther 33:870-9. 2011
    ..New medical therapies have improved outlook in inflammatory bowel disease but published impact on surgical rates has been modest suggesting that many patients are still not attaining remission...
  36. doi request reprint Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease
    X Roblin
    Department of Gastroenterology, F 42055, CHU Saint Etienne, France
    J Crohns Colitis 9:525-31. 2015
    ..Antibodies to infliximab [ATI] and trough levels to infliximab [TRI] are associated with loss of response in inflammatory bowel diseases [IBD]. The best way to predict loss of response [LOR] to infliximab [IFX] is unknown...
  37. doi request reprint Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease
    E Gizard
    INSERM U954 and Department of Hepato Gastroenterology, University Hospital of Nancy Brabois, Université de Lorraine, Vandoeuvre les Nancy, France
    Aliment Pharmacol Ther 40:3-15. 2014
    ..Extraintestinal manifestations are frequent in inflammatory bowel diseases (IBD). Most studies published so far focused on viral hepatitis and liver toxicity of IBD-related drugs...
  38. doi request reprint Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis
    L Peyrin-Biroulet
    Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandouvre lès Nancy, France
    Aliment Pharmacol Ther 44:807-16. 2016
    ..Understanding the true burden of surgical complications is important to clinicians in assessing risks and benefits of colectomy vs. continued medical therapy...
  39. doi request reprint The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients
    S Leclerc-Jacob
    Department of Rheumatology, Henri Poincare University, Nancy Teaching Hospital, Nancy, France
    Aliment Pharmacol Ther 39:957-62. 2014
    ..However, no study has evaluated the role of this imaging technique to assess sacroiliitis...
  40. doi request reprint The effect of immune therapy on surgical site infection following Crohn's Disease resection
    T Serradori
    Department of Digestive Surgery, University Hospital of Nancy Brabois, Nancy, France
    Br J Surg 100:1089-93. 2013
    ..Patients with Crohn's disease are increasingly receiving antitumour necrosis factor α (anti-TNF-α) therapy. Whether anti-TNF-α therapy increases the risk of postoperative infectious complications in Crohn's disease is a matter of debate...
  41. doi request reprint Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab
    G Bouguen
    Department of Hepato Gastroenterology, University Hospital of Rennes, Pontchaillou, France
    Aliment Pharmacol Ther 30:749-56. 2009
    ..In Crohn's disease, anal ulcers and stricture can be disabling...
  42. ncbi request reprint Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review
    Jerome Filippi
    Service de Gastroentérologie et Nutrition Clinique, Centre Hospitalier Universitaire de Nice, Faculte de Medecine, Université de Sophia Antipolis, Nice, F 06107, France
    Curr Drug Targets 12:1440-7. 2011
    ..Whether infliximab proves to be a disease modifying treatment in ulcerative colitis in the long term remains to be elucidated and will require further long-term prospective studies...